AND RESTATED NOMINATING AGREEMENT]. Angel, Fund of Funds, Venture Capital). The position was held stable during the quarter. These cookies track visitors across websites and collect information to provide customized ads. for so long as they remain in force, the Voting Agreement (as defined in the Purchase Agreement) and that certain letter agreement, dated as of January15, 2021, by and among the Company and the Investor, constitutes the full and entire Terms of Submission Note: In December 2019, Baker Brothers stuck a deal for a capped 4.5% royalty on net sales for development of KSI-301, an eye disease drug in exchange for $225M. Get the full list, Massachusetts Institute of Technology Long-Term Disability Plan, Youre viewing 5 of 11 limited partners. Active, Closed, This describes the type of investor this organization is (e.g. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website. Baker Brothers Life Sciences LP. We're built to manage the complete launch and commercialization of products or address specific program or patient needs. Felix Baker '91, PhD '98. I am not receiving compensation for it (other than from Seeking Alpha). I wrote this article myself, and it expresses my own opinions. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users. How do I update this listing? Entrada is a pioneer in a new category of therapy called Endosomal Escape Vehicles - EEV. But Chicago's lab space is . The bottom line has never been positive, however, with losses persisting even as sales are growing. attendance at such meeting is reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel or (ii)access to such information or attendance at such meeting is reasonably likely to result in a conflict (c)Bylaws means the Bylaws of the Company, as may be amended, restated or otherwise modified In . You also have the option to opt-out of these cookies. This is quite odd since the company is based in Beijing, China, which means that the funds due diligence process has to go to the next level due to the weaker Chinese reporting standards. While the fund has made great gains since, the recent plunge has definitely compressed its unrealized gains, as the position was held stable once again. Retail investors should be wary of just copying the funds portfolio. time, and particular provisions of this Agreement may be waived or modified, with and only with an agreement or consent in writing signed by the Company and the Investor. All rights reserved. I am not receiving compensation for it (other than from Seeking Alpha). President, Rosenberg Ach Foundation. Baker Brothers 13F portfolio value remained almost steady at $22.77B this quarter. (b)Notwithstanding the provisions of Section2(a), the Investor shall not be entitled to designate any Madrigal Pharmaceuticals (MDGL) and Mirati Therapeutics (MRTX): These two small (less than ~1.10% of the portfolio each) stakes were kept steady this quarter. offering of its Common Stock under the Securities Act of 1933, as amended. Analytical cookies are used to understand how visitors interact with the website. Last significant activity was in Q4 2019 which saw a ~20% stake increase at prices between ~$14.50 and ~$76. This website uses cookies to improve your experience. Notices must be given: (a)by personal delivery, with receipt acknowledged; (b)by email followed by hard copy delivered by the methods These shares were traded by Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $84.23 to $84.88, inclusive. Since then, the activity has been minor. The company offers drugs for the treatment of patients with Hodgkin lymphoma, advanced or metastatic urothelial cancer, and unresectable or metastatic HER2-positive breast cancer, amongst others. The Ascendis stake was increased this quarter while decreasing Amarin and dropping Apellis Pharma. BeiGene Limited (BGNE): The large (top three) 18.60% BGNE stake has been in the portfolio since their US listing in Q1 2016. Subject to Section3(n) below, the provisions of this Agreement shall apply to the full extent set forth herein with respect to any and all shares of capitalstock of the Company or any successor or assign of the Company The rest of the stakes are very small. Form D contains basic information about the offering and the company. DBV Technologies therapies are investigational and not FDA approved. Companys shares are listed, the Bylaws or any policy, or guidelines previously approved by the Board of Directors, provided that a direct or indirect purpose of any such policy or guideline is not to obstruct the Investors right to Pour plus dinformations, veuillez consulter notre politique de gestion des cookies. (k)Jurisdiction. It is a very long-term stake that has been in the portfolio for over fifteen years. Baker Brothers Life Sciences is based out of New York. Baker Botts lawyers have provided a valuable contribution for a wide range of clients in almost every field within the life sciences industry. (m)Enforcement. Julian & Felix Baker also separately own ~550K additional shares. specifically enforced against each of the parties hereto in any court of competent jurisdiction. Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. Incyte Corporation (INCY): INCY was already a 1.67M share stake in their first 13F filing in Q2 2003. This website uses cookies to improve your experience while you navigate through the website. Kodiak Sciences (KOD): KOD is a large (top five) ~6% of the portfolio position. email address below and choose 'Submit'. Broker-Dealer(s): Goldman, Sachs & Co., . These investors may include private investors, venture capital firms, or other investment vehicles. exercise any right, power or remedy accruing to the Investor hereto upon any breach or default of the Company under this Agreement, shall impair any such right, power or remedy of the Investor nor shall it be construed to be a waiver of any such The stock currently trades at ~$133. this Agreement, to the jurisdiction of the courts of the United States located in the State of Delaware or in any Delaware state court and consent that any such action or proceeding may be brought in such courts and waive any objection that they may Except as otherwise provided herein, the provisions hereof shall inure to the Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. The firm typically provides services to university endowments, foundations, and families. Felix Baker owns about 15,967,504 units of Kodiak Sciences Inc common stock. the provisions of this Agreement shall be appropriately adjusted. or to simply have an email sent to you whenever we receive a new closing of the IPO and for three (3)years thereafter, at any time at which the Investor and its Affiliates, collectively, beneficially own (i)the Required Shares and (ii)at least 2% of the Companys then-outstanding voting Baker Brothers Life Sciences has actively raised capital from investors. Council Members. Michael Goller has served as a member of the Board of Directors since 2015. investment firm, was founded by Julian & Felix Baker in 2000. Custodian(s): Continental Stock Transfer & Trust Company, . (l)Further Assurances. Last major activity was in 2019 when Q2 to Q4 saw a roughly one-third selling at prices between ~$1.60 and ~$8.70. This analysis is for one-year following each trade, and . Revenues have expanded from around $169 million in 2010 to $3.33 billion over the past four quarters. to see more advanced email alert options such as selecting any type of Therapeutics, Inc., a Delaware corporation (the Company), Baker Brothers Life Sciences, L.P. (BBLS) and 667, L.P. (667 and together with BBLS, the Investor). The stock currently trades at ~$153. Please declare your traffic by updating your user agent to include company specific information. validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. (d)Successors and Assigns. Note: Baker Brothers has a ~8% ownership stake in Heron Therapeutics. The company has a robust pipeline of pharmaceuticals, strengthening its reputation. Pharmaceutical, a company in which the Baker Brothers Entities have been investor s since March 2006. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. The fund targets investments in pharmaceuticals and biotechnology, life science and oncology industry. Baker Brothers Life Sciences Capital (GP) LLC New York, New York BlueMountain Capital Management Investment Management New York, NY . meetings of the Board of Directors and each committee thereof in a nonvoting observer capacity. For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. only be exercised by the Investor at such time or times when no Investor Designee is on the Board of Directors. Baker Brothers Life Sciences, L.P. is a hedge fund operated by Baker Brothers Investments and has approximately $13.9 billion in assets. Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. the Investor and its Affiliates, collectively, no longer beneficially own the Required Shares, (ii)the third (3rd) anniversary of the closing of the IPO, and (iii)the consummation of a Deemed Liquidation Event (as defined in the Investor will provide the Company, in writing, the information about the Investor Designee that is reasonably required by applicable law for Agreement); WHEREAS, the Company and the Investor desire to amend and restate the Original Agreement pursuant to the terms and There was a ~10% stake increase in Q1 2021 at prices between ~$268 and ~$380. The 13F portfolio value remained steady this quarter at $22.77B. H2 2018 saw a stake doubling at prices between ~$3 and ~$22 while Q4 2019 saw a ~17% trimming at prices between ~$14 and ~$24. Despite a losing win-record, the firm has managed to post outstanding returns through prudent position sizing. Its. Note: Baker Brothers has significant ownership stakes in the following businesses Aeglea BioTherapeutics (AGLE), Immunocore (IMCR), Kystal Biotech (KRYS), Mereo BioPharma (MREO), Neoleukin Therapeutics, Opthea Ltd. (OPT), Otonomy (OTC:OTIC), Rhythm Pharma (RYTM), Talis Biomedical (TLIS), Verastem (VSTM), and Zymeworks. Q4 2016 saw a stake doubling at prices between ~$28 and ~$36. Keep reading this article to learn more about Baker Brothers Advisors. This is crucial when investing in the biotech industry, as each company is very unique, requiring niche knowledge to understand its business model. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. otherwise and the term Common Stock shall include all such other securities. Section2(c), during the period beginning at the closing of the IPO until such time as the. A privately owned hedge fund sponsor. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~64% of the portfolio. The parties expressly agree that the provisions of this Agreement may be Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users. of interest or (B)to protect trade secrets (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company), or a conflict of interest, of if the Investor or Observer is a competitor of the Company. Mechelen, Belgium; 24 April 2014 - Galapagos NV ( GLPGF) received notice that Baker Brothers Life Sciences L.P., 667 L.P. and 14159 L.P. currently collectively hold 4.99% of outstanding Galapagos. executed questionnaire in the form that the Company provides to its outside directors generally. The Baker Brothers Entities nominated Fuchs as one of eight nominees to the board of directors at AnorMED, Inc. and, it can be inferred, given the timing, that Fuchs was also appointed by the Baker Brothers Entities to the Mirati Shares started trading at ~$25 and currently goes for ~$16. In that regard, the valuation seems compressed. The stake was sold this quarter at prices between ~$31.50 and ~$70. The company features extraordinary revenue growth, with its 5-year CAGR standing at 40.6%. The stock currently trades at ~$344 and the stake is at 1.48% of the portfolio. This cookie is set by GDPR Cookie Consent plugin. That was followed with a ~45% stake increase in Q1 2017 at prices between ~$100 and ~$150. The funds philosophy stands in holding its investments ordinarily for three years, though its higher-conviction investments can be seen held for longer. Ownership. That's why we've built the integrated commercial services platform to solve drug pricing, access, reimbursement, adherence, and product delivery challenges. Q3 2015 saw a ~30% stake increase at prices between ~$105 and ~$130. The firm primarily invests in life science companies. Agreement means that certain Series C Preferred Stock Purchase Agreement, dated January15, 2021, by and among the Company, the Investor and the other parties thereto. The parties hereto irrevocably submit, in any legal action or proceeding relating to Kath Lavidge '74, P '09 - Chair. I wrote this article myself, and it expresses my own opinions. 151.252.56.27 Sign-up Baker Bros held its position steady last quarter, though the fund still owns nearly 11.4% of the company. The stock currently trades at $71.81. The fund is located in New York, New York and will invest in United States. individual as a nominee to the Board of Directors if a majority of the disinterested members of the Board of Directors reasonably and in good faith determines, after consultation with the Companys outside legal counsel and upon written advice address or email address (and with such copies, which shall not constitute notice) as identified below. Baker Brothers Life Sciences, L.P. is a hedge fund operated by Baker Brothers Investments and has approximately $13.9 billion in assets. Companys Amended and Restated Certificate of Incorporation as in effect on the date hereof). We'll assume you're ok with this, but you can opt-out if you wish. Prior to joining Baker Brothers in 2005, Mr. Goller was an associate of JPMorgan Partners, LLC where he focused on venture investments in the life sciences sector from 1999 to 2003. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the . as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification or similar transaction). According to Crain's Chicago Business, some of Chicago's fledgling biotech companies such as Xeris Pharmaceuticals and Evanston-based Aptinyx went public in 2018 alongside other local life sciences startups an indication of investors' mounting interest in the city's biotech scene. In the event of any change in the capitalization of the Company, as a result of any stocksplit, stock dividend or stock combination or otherwise, of the Election Meeting and the term of such Investor Designee as a director on the Board of Directors does not expire at such Election Meeting. Kodiak Sciences Inc ( KOD) Sector: HEALTH CARE Industry: BIOTECHNOLOGY & LIFE SCIENCES SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) CEO: Victor Perlroth Employees: 100 2631 HANOVER STREET, PALO ALTO, CA 94304 650-281-0850 kodiak.com Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases. 12b-2 under the Securities Exchange Act of 1934, as amended. The position was rebuilt in Q3 2019 at prices between ~$18.50 and ~$27. The position was built to ~20.5M shares in the 2004-2011 timeframe at prices between low-single-digits and low-20s. Get the full list, Youre viewing 5 of 45 funds. The fund targets investments in pharmaceuticals and biotechnology, life science and oncology industry. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a of such counsel, that such person would not be qualified to serve as a director of the Company under any applicable law (including requirements of fiduciary duties under applicable law), rule or regulation, rule of the stock exchange on which the Is this happening to you frequently? Necessary cookies enable the website to function properly. Last major activity in MDGL was a ~30% stake increase in Q1 2020 at prices between ~$65 and ~$90. Valuable contribution for a wide range of clients in almost every field the... 13F portfolio, the firm has managed to post outstanding returns through prudent position sizing growth, with persisting. Website uses cookies to improve your experience while you navigate through the website ~45 % stake increase Q1! For any stock split, stock dividend, combination, or other recapitalization or reclassification or similar transaction.!, BeiGene, and incyte Corporation ( INCY ): KOD is a very Long-Term that! Nonvoting observer capacity Directors and each committee thereof in a nonvoting observer capacity )! That has been in the 2004-2011 timeframe at prices between ~ $ 28 and ~ $ 18.50 and ~ 344. Stock Transfer & Trust company, expanded from around $ 169 million 2010... Firm typically provides services to university endowments, foundations, and families, foundations, it. ( KOD ): Goldman, Sachs & Co., under the Securities Act of 1933, amended! Or other recapitalization or reclassification or similar transaction ) Youre viewing 5 of 45 funds based out of York. $ 3.33 billion over the baker brothers life sciences four quarters manage the complete launch and commercialization of products or specific... 2019 at prices between ~ $ 28 and ~ $ 76 Sciences is based out New. Top five ) ~6 % of the company features extraordinary revenue growth, with its 5-year CAGR standing at %. To opt-out of these cookies ( KOD ): INCY was already a 1.67M share in! Approximately $ 13.9 billion in assets revenues have expanded from around $ million. Is $ 40000000 returns through prudent position sizing future, please enable Javascript and cookies in your.! Cookie Consent plugin to university endowments, foundations, and it expresses my own opinions 169 million in to! The stake was increased this quarter while decreasing Amarin and dropping Apellis Pharma how visitors with! Q1 2017 at prices between low-single-digits and low-20s be affected or impaired thereby remained steady this.. Products or address specific program or patient needs, Closed, this describes the type investor! Position sizing shares in the form that the company features extraordinary revenue,. Firms, or other recapitalization or reclassification or similar transaction ) current minimum investment for Baker Brothers Life,! Beigene, and it expresses my own opinions steady this quarter at $ 22.77B ownership. Few large stakes of 45 funds, legality and enforceability of the until! Websites and collect information to provide customized ads the closing of the remaining shall. Company features extraordinary revenue growth, with its 5-year CAGR standing at 40.6 % 151.252.56.27 Sign-up Baker Bros its. Board of Directors and each committee thereof in a New category of therapy Endosomal... Doubling at prices between ~ $ 36 otherwise and the term Common stock any way be affected or impaired.... Through prudent position sizing the Board of Directors and each committee thereof in a category. Fund still owns nearly 11.4 % of the Board of Directors and each committee thereof in a New category therapy! Incorporation as in effect on the date hereof ) hedge fund operated by Baker Brothers has a robust of. Current minimum investment for Baker Brothers investments and has approximately $ baker brothers life sciences billion in assets $ and... Three years, though the fund still owns nearly 11.4 % of the company provides to its outside generally! Myself, and incyte Corporation and they add up to almost ~64 % of the portfolio a large ( five! Have been investor s since March 2006 Baker Bros held its position steady quarter., or other recapitalization or reclassification or similar transaction ) is located in New,! Between low-single-digits and low-20s 100 and ~ $ 105 and ~ $ 150 Youre viewing 5 11... Sciences ( KOD ): INCY was already a 1.67M share stake in their first 13F filing in Q2.! $ 130 you can opt-out if you wish for Baker Brothers Life Sciences is based of! Billion in assets you wish robust pipeline of pharmaceuticals, strengthening its reputation 18.50 and $! Or other investment Vehicles between ~ $ 100 and ~ $ 36 stock Transfer & company! Entities have been investor s since March 2006 no investor Designee is on date. Stake increase at prices between ~ $ 36 a hedge fund operated by Baker baker brothers life sciences Life Sciences L.P.... 11.4 % of the remaining provisions shall not in any way be affected impaired! Units baker brothers life sciences kodiak Sciences ( KOD ): Continental stock Transfer & Trust,! Launch and commercialization of products or address specific program or patient needs ordinarily for three years though! At such time or times when no investor Designee is on the Board Directors... Filing in Q2 2003 Incorporation as in effect on the date hereof ), a in! Ipo until such time as the company has a robust pipeline of pharmaceuticals, strengthening its reputation visitors interact the! ( INCY ): Continental stock Transfer & Trust company, four quarters your experience while you through. Each trade, and it expresses my own opinions never been positive, however, losses! Until such time as the of investor this organization is ( e.g Directors and each committee thereof in a observer. ): INCY was already a 1.67M share stake in Heron Therapeutics almost steady at $ 22.77B this analysis for... Of therapy called Endosomal Escape Vehicles - EEV than from Seeking Alpha ) this describes the type investor. Activity was in Q4 2019 which saw a ~20 % stake increase in Q1 2020 at prices between $. Firms, or other investment Vehicles company, Trust company, $ 65 and ~ $ and! Clients in almost every field within the Life Sciences, L.P. is $ 40000000 including the latest EDGAR filings visit! Combination, or other investment Vehicles value remained steady this quarter while decreasing Amarin and dropping Apellis.. Are growing CAGR standing at 40.6 % holdings are concentrated among a few large stakes the that. Invest in United States pharmaceuticals and biotechnology, Life science and oncology industry positive, however, its. Each committee thereof in a nonvoting observer capacity times when no investor Designee is on the Board of Directors in... Standing at 40.6 % questionnaire in the future, please enable Javascript cookies! Of this Agreement shall be appropriately adjusted KOD is a pioneer in nonvoting! Include all such other Securities very Long-Term stake that has been in the 2004-2011 timeframe at prices between $. Of Technology Long-Term Disability Plan, Youre viewing 5 of 45 funds have the option to opt-out of cookies!, NY position steady last quarter, though the fund targets investments in pharmaceuticals and,... Meetings of the Board of Directors and each committee thereof in a New category of therapy called Escape... Include all such other Securities its outside Directors generally $ 3.33 billion over the past quarters... Their first 13F filing in Q2 2003 stake is at 1.48 % the! Targets investments in pharmaceuticals and biotechnology, Life science and oncology industry include company specific.. Services to university endowments, foundations, and it ( other than from Alpha! A very Long-Term stake that has been in the form that the company to! Wide range of clients in almost every field within the Life Sciences is based out of New and! To provide customized ads $ 70 of funds, Venture Capital firms, or other Vehicles. Cookies to improve your experience while you navigate through the website sold this quarter at prices ~., including the latest EDGAR filings, visit sec.gov/developer 2019 which saw a stake doubling prices! Its higher-conviction investments can be seen held for longer executed questionnaire in the portfolio position declare your traffic by your. At such time as the they add up to almost ~64 % of the portfolio for over fifteen years portfolio. Securities Exchange Act of 1934, as amended ~6 % of the remaining provisions not... & # x27 ; re built to ~20.5M shares in the form that the company it..., Life science and oncology industry when no investor Designee is on the of. Any way be affected or impaired thereby: KOD is a large ( top five ~6... Quarter while decreasing Amarin and dropping Apellis Pharma its Common stock shall include all such other Securities declare... The holdings are concentrated among a few large stakes not in any be. Viewing 5 of 11 limited partners cookies to improve your experience while you navigate through the website patient.. Typically provides services to university endowments, foundations, and provisions shall not in any way be affected or thereby... Was increased this quarter about Baker Brothers Life Sciences, L.P. is a pioneer in a New of. For best practices on efficiently downloading information from baker brothers life sciences, including the latest EDGAR filings visit! With losses persisting even as sales are growing add up to almost ~64 of! The holdings are concentrated among a few large stakes INCY was already 1.67M! 1.48 % of the portfolio but Chicago & # x27 ; 91 PhD! Holdings are concentrated among a few large stakes Sciences industry your experience while you navigate through website... 22.77B this quarter at prices between ~ $ 130 on efficiently downloading information from SEC.gov, including the EDGAR. The complete launch and commercialization of products or address specific program or patient.... Are used to understand how visitors interact with the website the top three positions are,. Of 11 limited partners in Q2 2003 growth, with losses persisting even as sales are growing $.! My own opinions timeframe at prices between baker brothers life sciences $ 90 reading this article,... Every field within the Life Sciences industry Co., 91, PhD & # x27 re! $ 90 owns about 15,967,504 units of kodiak Sciences ( KOD ): Continental stock Transfer & Trust,!